Current pharmacotherapy of attention deficit hyperactivity disorder

Drugs of Today

Volumn 49, Issue 10, 2013, Pages 647-665

  Reddy, D S ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder (ADHD); Lisdexamfetamine; Methylphenidate; Modafinil

Indexed keywords

1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMFEBUTAMONE; AMPHETAMINE; AR 08; ATOMOXETINE; AZD 5213; BREXPIPRAZOLE; CENTRAL STIMULANT AGENT; CHOLINESTERASE INHIBITOR; CLONIDINE; D ATS; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DONEPEZIL; DOPAMINE; EB 1020; EDIVOXETINE; GUANFACINE; LISDEXAMFETAMINE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; ND 0801; NEW DRUG; NORTRIPTYLINE; NT 0102; NWP 09; OLANZAPINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SEDARISTON; SPN 812V; TD 9855; THREO 3,4 DIHYDROXYPHENYLSERINE; TIPEPIDINE; TIPEPIDINE HIBENZATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL CRAMP; AGGRESSION; ANOREXIA; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; BEHAVIOR THERAPY; CEREBROVASCULAR ACCIDENT; CHILD PSYCHIATRY; CHILL; CLINICAL FEATURE; CONSTIPATION; DECREASED APPETITE; DELUSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ABUSE; DRUG APPROVAL; DRUG CHOICE; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; DSM-IV; ENVIRONMENTAL FACTOR; EUPHORIA; EVENING DOSAGE; FAINTNESS; FATIGUE; FEVER; FLUSHING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GENETIC LINKAGE; GROWTH INHIBITION; GROWTH RATE; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPERACTIVITY; HYPERHIDROSIS; HYPERREFLEXIA; HYPERTENSION; IMPOTENCE; IMPULSIVENESS; INSOMNIA; IRRITABILITY; LIVER TOXICITY; MANIA; MENSTRUATION DISORDER; MENTAL DISEASE; METALLIC TASTE; MOOD CHANGE; MORNING DOSAGE; MOTOR PERFORMANCE; MUSCLE CRAMP; MYDRIASIS; NARCOLEPSY; NAUSEA; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RECOMMENDED DRUG DOSE; RESTLESSNESS; REVIEW; SEDATION; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SHOCK; SIDE EFFECT; SPEECH; SUDDEN DEATH; SUICIDAL BEHAVIOR; SYMPTOM; TIC; TREATMENT DURATION; TREATMENT INDICATION; TREMOR; URINARY HESITANCY; URINE RETENTION; VOMITING; WEAKNESS; WEIGHT REDUCTION; XEROSTOMIA;

ATOMOXETINE; ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD); LISDEXAMFETAMINE; METHYLPHENIDATE; MODAFINIL;

AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR THERAPY; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; METHYLPHENIDATE; PROPYLAMINES;

EID: 84890387541     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.10.2008996     Document Type: Review

References (97)

1. Pary, R., Lewis, S., Matuschka, P.R., Rudzinskiy P., Safi M., Lippmann S. Attention deficit disorder in adults. Ann Clin Psychiatry 2002, 14(2): 105-11
2. NiMH. National Institute of Mental Health Attention Deficit Hyperactivity Disorder (ADHD). National institutes of Health, USA, 2008, 1-12
3. Wilens, T.E., Biederman, J., Spencer, T.J. Attention deficit/ hyperactivity disorder across the lifespan. Ann rev Med 2002, 53: 113-31.
4. Willcutt, E.G. The prevalence of DSM-IV attentiondeficit/ hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012, 9(3): 490-9
5. Staller, J., Faraone, S.V. Attention-deficit hyperactivity disorder in girls: epidemiology and management. CNS Drugs 2006, 20(2): 107-23.
6. Green, A.L, rabiner, D.L. What do we really know about ADHD in college students? Neurotherapeutics 2012, 9(2): 559-68.
7. Philipsen, A. Differential diagnosis and comorbidity of attention- deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD) in adults. Eur Arch Psychiatry Clin Neurosci 2006, 256(Suppl. 1): i42-6
8. Shreeram, S., He, J.P., Kalaydjian, A., Brothers, S., Merikangas, K.r. Prevalence of enuresis and its association with attention-deficit/hyperactivity disorder among U.S. children: results from a nationally representative study. J Am Acad Child Adolesc Psychiatry 2009, 48(1): 35-41.
9. Neuman, R.J., Lobos, E., Reich, W., Henderson, C.A., Sun, L.w., Todd, r.D. Prenatal smoking exposure and dopaminergic genotypes interact to cause a severe ADHD subtype. Biol Psychiatry 2007, 61(12): 1320-8.
10. Gizer, I.R., Ficks, C., waldman, I.D. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 2009, 126(1): 51-90.
11. Eubig, P.A, Aguiar, A., Schantz, S.L. Lead and PCBs as risk factors for attention deficit/ hyperactivity disorder. Environ Health Perspect 2010, 118(12): 1654-67.
12. Neale, B.M., Medland, S.E., ripke, S. et al. Meta-analysis of genome-wide association studies of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2010, 49(9): 884-97
13. Cortese, S., Kelly, C., Chabernaud, C., Proal, E., Di Martino, A., Milham, M.P., Castellanos, F.X. Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies. Am J Psychiatry 2012, 169(10): 1038-55.
14. Khan, S.A., Faraone, S.V. The genetics of attentiondeficit/ hyperactivity disorder: a literature review of 2005. Curr Psychiatry rep 2006, 8(5): 393-7.
15. Faraone, S.V., Perlis, R.H., Doyle, A.E., Smoller, J.W., Goralnick, J.J., Holmgren, M.A., Sklar, P. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57(11): 1313-23.
16. Akutagava-Martins, G.C., Salatino-Oliveira, A., Kieling, C.C., rohde, L.A., Hutz, M.H. Genetics of attentiondeficit/ hyperactivity disorder: current findings and future directions. expert rev Neurother 2013, 13(4): 435-445.
17. Shaw P., Gornick M., Lerch J. et al. Polymorphisms of the dopamine D4 receptor: clinical outcome and cortical structure in attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 2007, 64(8): 921-31.
18. Mick, E., Biederman, J., Faraone, S.V., Sayer, J., Kleinman, S. Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J Am Acad Child Adolesc Psychiatry 2002, 41(4): 378-85.
19. Linnet, K.M., Dalsgaard, S., Obel, C. et al. Maternal lifestyle factors in pregnancy risk of attention-deficit/hyperactivity disorder and associated behaviors: review of the current evidence. Am J Psychiatry 2003, 160(6): 1028-40.
20. Braun, J.M., Kahn, r.S., Froehlich, T., Auinger, P., Lanphear, B.P. Exposures to environmental toxicants and attentiondeficit/ hyperactivity disorder in U.S. children. Environ Health Perspect 2006, 114(12): 1904-9.
21. Polańska, K., Jurewicz, J., Hanke, w. Review of current evidence on the impact of pesticides, polychlorinated biphenyls and selected metals on attention deficit / hyperactivity disorder in children. int J Occup Med environ Health 2013, 26(1): 16-38.
22. Nair, J., ehimare, U., Beitman, B.D., Nair, S.S., Lavin, A. Clinical review: evidence-based diagnosis and treatment of ADHD in children. Mo Med 2006, 103(6): 617-21.
23. Rader, R., Mccauley, L., Callen, E.C. Current strategies in the diagnosis and treatment of childhood attentiondeficit/ hyperactivity disorder. Am Fam Physician 2009, 79(8): 657-65.
24. Gentile, J.P., Atiq, R., Gillig, P.M. Adult ADHD: diagnosis, differential diagnosis and medication management. Psychiatry 2006, 3(8): 25-30.
25. Philipsen, A. Psychotherapy in adult attention deficit hyperactivity disorder: implications for treatment and research. Expert rev Neurother 2012, 12(10): 1217-25.
26. Brown, R.T., Amler, R.w., Freeman, w.S. et al. American Academy of Pediatrics Committee on Quality Improvement, American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder. Treatment of attention- deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005, 115(6): e749-57.
27. Sonuga-Barke, E.J., Brandeis, D., Cortese, S. et al. european ADHD Guidelines Group. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 2013, 170(3): 275-89.
28. Pliszka, S.R. Pharmacologic treatment of attentiondeficit/ hyperactivity disorder: Efficacy, safety and mechanisms of action. Neuropsychol rev 2007, 17(1): 61-72.
29. Baron, D.A., Pato, M.T., Cyr, R.L. Treatment of adults with attention-deficit/hyperactivity disorder. J Am Osteopath Assoc 2011, 111(11): 610-4.
30. Stevenson, R.D., Wolraich, M.L. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Pediatr Clin North Am 1989, 36(5): 1183-97.
31. Ahmed, R., McCaffery, K.J., Aslani, P. Factors influencing parental decision making about stimulant treatment for attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2013, 23(3): 163-78.
32. Treuer, T., Gau, S.S., Méndez, L. et al. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/ hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability J Child Adolesc Psychopharmacol 2013, 23(3): 179-93.
33. Schonwald, A., Lechner, E. Attention deficit/hyperactivity disorder: complexities and controversies. Curr Opin Pediatr 2006, 18(2): 189-95.
34. Dopheide, J.A. A calming influence: An analysis of ADHD treatments. Pharmacy Times, August 1, 2006. http://www.pharmacytimes.com/publications/issue/ 2006/2006-08/2006-08-5811
35. Mayes, R., Bagwell, C., Erkulwater, J. ADHD and the rise in stimulant use among children. Harv rev Psychiatry 2008, 16(3): 151-66.
36. Brown, C.H. Attention-deficit/hyperactivity disorder and treatment. Pharmacy Times, March 14, 2011. http://www.pharmacytimes.com/publications/issue/ 2011/March2011/ ADHD-0311#sthash.MBM7JQtm.dpuf
37. Cortese, S., Holtmann, M., Banaschewski, T. et al. European ADHD Guidelines Group. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 2013, 54(3): 227-46.
38. Strohl, M.P. Bradley's Benzedrine studies on children with behavioral disorders. Yale J Biol Med 2011, 84(1): 27-33.
39. Hodgkins, P., Shaw, M., Mccarthy, S., Sallee, F.R. The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter? CNS Drugs 2012, 26(3): 245-68.
40. Heal, D.J., Smith, S.L., Gosden, J., Nutt, D.J. Amphetamine, past and present - a pharmacological and clinical perspective. J Psychopharmacol 2013, 27(6): 479-96.
41. Hoffman, B.B., Lefkowitz, R.J. Catecholamines and sympathomimetic drugs. in: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edition. Gilman, A.G., ral, T.w., Nies, A.S., Taylor, P. (eds.), Pergamon Press 1990, 187-220.
42. westfall, T.C., westfall, D.P. Adrenergic agonists and antagonists.Amphetamines. in: Goodman and Gilman's The Pharmacological Basis of Therapeutics., 11th edition. McGraw-Hill 2005, 257-63.
43. Drevets, W.C., Gautier, C., Price, J.C., Kupfer, D.J., Kinahan, P.E., Grace, A.A., Price, J.L., Mathis, C.A. Amphetamineinduced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001, 49(2): 81-96.
44. Sulzer, D., Sonders, M.S., Poulsen, N.W., Galli, A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005, 75(6): 406-33.
45. Sikstrom, S., Söderlund, G. Stimulus-dependent dopamine release in attention-deficit/hyperactivity disorder. Psychol rev 2007, 114(4): 1047-75.
46. Minzenberg, M.J. Pharmacotherapy for attentiondeficit/ hyperactivity disorder: from cells to circuits. Neurotherapeutics 2012, 9(3): 610-21
47. Del Campo, N., Chamberlain, S.R., Sahakian, B.J., Robbins, T.W. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 2011, 69(12): e145-57.
48. Berman, S.M., Kuczenski, R., McCracken, J.T., London, E.D. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry 2009, 14(2): 123-42.
49. Larsen, K.E., Fon, E.A., Hastings, T.G., edwards, r.H., Sulzer, D. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci 2002, 22(20): 8951-60.
50. Elia, J., Ambrosini, P.J., Rapoport, J.L. Treatment of attention- deficit-hyperactivity disorder. N engl J Med 1999, 340(10): 780-8.
51. Stein, M.A., waldman, I.D., Charney, E., Aryal, S., Sable, C., Gruber, R., Newcorn, J.H. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol 2011, 21(6): 581-8.
52. Spencer, T.J., wilens, T.E., Biederman, J., weisler, R.H., read, S.C., Pratt, R. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006, 28(2): 266-79
53. Biederman, J., Wigal, S.B., Spencer, T.J., McGough, J.J., Mays, D.A. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Clin Ther 2006, 28(2): 280-93.
54. Steer. C., Froelich, J., Soutullo, C.A., Johnson, M., Shaw, M. Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder. CNS Drugs 2012, 26(8): 691-705.
55. Childress, A.C., Sallee, F.R. The use of lisdexamfetamine dimesylate for the treatment of ADHD. expert rev Neurother 2012, 12(1): 13-26.
56. Jain, R., Babcock, T., Burtea, T., Dirks, B., Adeyi, B., Scheckner, B., Lasser, R. Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis. Child Adolesc Psychiatry Ment Health 2011, 5(1): 35.
57. Babcock, T., Dirks, B., Adeyi, B., Scheckner, B. Efficacy of lisdexamfetamine dimesylate in adults with attentiondeficit/ hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study. BMC Pharmacol Toxicol 2012, 13: 18.
58. Vitiello, B. Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder. CMAJ 2001, 165(11): 1505-6.
59. Punja, S., Zorzela, L., Hartling, L., Urichuk, L., vohra, S. Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy. BMJ Open 2013, 3(3).
60. Greenhill, L., Kollins, S., Abikoff, H. et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006, 45(11): 1284-93.
61. Wigal, T., Greenhill, L., Chuang, S. et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 2006, 45(11): 1294-303.
62. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999, 56(12): 1073-86
63. Mcgough, J., Mccracken, J., Swanson, J. et al. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006, 45(11): 1314-22.
64. Molina, B.S., Hinshaw, S.P., eugene Arnold, L. et al. MTA Cooperative Group. Adolescent substance use in the multimodal treatment study of Attention-Deficit/Hyperactivity Disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry 2013, 52(3): 250-63.
65. Molina, B.S., Hinshaw, S.P., Swanson, J.M. et al. MTA Cooperative Group. The MTA at 8 years: prospective followup of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009, 48(5): 484-500.
66. Valdizán-Usón , J.R., Cánovas-Martínez, A., De Lucas-Taracena, M.T. et al. Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study. Neuropsychiatr Dis Treat 2013, 9: 211-8
67. Kuczenski, R., Segal, D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 1997, 68(5): 2032-7
68. Iversen, L. Neurotransmitter transporters and their impact on the development of psychopharmacology. Br J Pharmacol 2006, 147(Suppl. 1): S82-8.
69. Cox, D.J., Merkel, R.L., Moore, M., Thorndike, F., Muller, C., Kovatchev, B. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics 2006, 118(3): e704-10.
70. Steele, M., Weiss, M., Swanson, J., wang, J., Prinzo, R.S., Binder, C.E. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate- release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006, 13(1): e50-62
71. Coghill, D., Seth, S. Osmotic, controlled-release methylphenidate for the treatment of ADHD. expert Opin Pharmacother 2006, 7(15): 2119-38
72. Adler, L.A., Zimmerman, B., Starr, H.L., Silber, S., Palumbo, J., Orman, C., Spencer, T. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharma - col 2009, 29(3): 239-47.
73. Maldonado, R. Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate. Expert Opin Drug Metab Toxicol 2013, 9(8): 1001-14.
74. Heal, D.J., Pierce, D.M. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 2006, 20(9): 713-38
75. Patrick, K.S., Straughn, A.B., Perkins, J.S., González, M.A. Evolution of stimulants to treat ADHD: transdermal methylphenidate. Human Psychopharmacol 2009, 24(1): 1-17.
76. Swanson, J., Greenhill, L., wigal, T. et al. Stimulant-related reductions in growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 2006, 45(11): 1304-13.
77. Wigal, S.B., Raja, P., Shukla, A. An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder. Expert Opin Pharmacother 2013, 14(1): 137-45
78. Mcketin, R., Mclaren, J., Lubman, D.I., Hides, L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006, 101(10): 1473-8.
79. Martinez-raga, J., Knecht, C., Szerman, N., Martinez, M.I. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs 2013, 27(1): 15-30.
80. Kahbazi, M., Ghoreishi, A., Rahiminejad, F., Mohhammadi, M.R., Kamalipour, A., Akhondzadeh, S. A randomized, double- blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry res 2009, 168(3): 234-7.
81. Biederman, J., Pliszka, S.R. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. J Pediatr 2008, 152(3): 394-9
82. Carstairs, S.D., Urquhart, A., Hoffman, J., Clark, R.F., Cantrell, F.L. A retrospective review of supratherapeutic modafinil exposures. J Med Toxicol 2010, 6(3): 307-10.
83. Arnold, V.K., Feifel, D., Earl, C.Q., Yang, R., Adler, L.A. A 9- week, randomized, double-blind, placebo-controlled, parallel- group, dose-finding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD. J Atten Disord 2012, Advance publication.
84. Bailey, K.P. Pharmacological treatments for ADHD and the novel agent atomoxetine. J Psychosoc Nurs Ment Health Serv 2003, 41(8): 12-7.
85. Garnock-Jones, K.P., Keating, G.M. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009, 11(3): 203-26.
86. Bushe, C.J., Savill, N.C. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: Focus on clinical efficacy and safety. J Psychopharmacol 2013, Advance publication.
87. Ghuman, J.K., Breitborde, N.J. Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD. evid Based Ment Health 2012, 15(3): 74.
88. Arnsten, A.F. The use of α2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert rev Neurother 2010, 10(10): 1595-605.
89. Connor, D.F., Findling, r.L., Kollins, S.H., Sallee, F., López, F.A., Lyne, A., Tremblay, G. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010, 24(9): 755-68.
90. Müller, U., Clark, L., Lam, M.L. et al. Lack of effects of guanfacine on executive and memory functions in healthy male volunteers. Psychopharmacology 2005, 182(2): 205-13.
91. Wilens, T.E., Haight, B.R., Horrigan, J.P. et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005, 57(7): 793-801.
92. Klein-Schwartz, W. Abuse and toxicity of methylphenidate. Curr Opin Pediatr 2002, 14(2): 219-23
93. Fone, K.C., Nutt, D.J. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol 2005, 5(1): 87-93
94. Mcketin, R., Lubman, D.I., Baker, A.L., Dawe, S., Ali, R.L. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiatry 2013, 70(3): 319-24.
95. Quinton, M.S., Yamamoto, B.K. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 2006, 8(2): e337-47
96. Cadet, J.L., Krasnova, I.N., Jayanthi, S., Lyles, J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox res 2007, 11(3-4): 183-202.
97. Steinkellner, T., Freissmuth, M., Sitte, H.H., Montgomery, T. The ugly side of amphetamines: short- and long-term toxicity of 3,4- methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine. Biol Chem 2011, 392(1-2): 103-15.